MedTrace Logo

AI Model for Classifying Breast Cancer From Histopathology Images

NCT06717984 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2024-12-05

No results posted yet for this study

Summary

Breast cancer, a prevalent and potentially fatal disease, underscores the need for early and accurate detection to improve patient outcomes. Traditional histopathological examination, the current gold standard for diagnosis, faces limitations like subjectivity and low efficiency. In response, this research seeks to revolutionize breast cancer diagnostics by using deep learning techniques to classify invasive and noninvasive breast cancer types from histopathological images. Non-invasive cancers, like DCIS and LCIS, are confined to milk ducts or lobules, while invasive cancers spread to surrounding tissue and make up 70% of cases, often leading to poorer outcomes.

The proposed AI model aims to enhance diagnostic accuracy and efficiency, surpassing manual methods, and providing a scalable solution for diverse healthcare settings. By automating image analysis, the model seeks to democratize cancer screening, making it accessible in underserved populations and adaptable to different resources and equipment. Ultimately, this research aims to advance breast cancer detection, improve patient care, and contribute to better treatment outcomes globally.

Conditions

Interventions

DIAGNOSTIC_TEST

Biopsy, Mastectomy, Histopathology

Biopsy: This intervention involves the collection of breast tissue samples through a biopsy procedure. These samples are obtained from women undergoing investigation for unusual cell growth and are analyzed to detect potential abnormalities, including benign, in situ, or invasive cancerous changes. Mastectomy: This intervention refers to the surgical removal of breast tissue, typically performed to treat or prevent the spread of breast cancer. It may involve the removal of part or all of the breast and is considered in cases of invasive breast cancer or high-risk noninvasive breast cancer. Histopathology: This intervention focuses on the microscopic examination of breast tissue samples collected through biopsy or mastectomy. Histopathological analysis is conducted to assess cellular abnormalities, determine the presence of cancer, and classify the tissue as benign, in situ, or invasive, providing the basis for diagnosis and treatment decisions.

Sponsors & Collaborators

  • National Institute of Cancer Research & Hospital, Bangladesh

    collaborator UNKNOWN

  • Taufiq Hasan, PhD

    lead OTHER

Principal Investigators

  • Taufiq Hasan, PhD · Department of Biomedical Engineering, Bangladesh University of Engineering and Technology (BUET), Dhaka - 1205.

  • Farida Arjuman, FCPS, MCPS · Department of Histopathology, National Institute of Cancer Research and Hospital (NICRH)

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-11
Primary Completion
2025-02-11
Completion
2025-02-11

Countries

  • Bangladesh

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06717984 on ClinicalTrials.gov